The Ethics of Data Monetization

23andMe's pivot towards monetizing its genetic database raises profound ethical questions. While the company argues that this approach could lead to valuable medical discoveries, it also turns customers' most personal information into a commodity. This shift challenges us to consider:

• What constitutes fair compensation for individuals whose genetic data contributes to profitable discoveries?
• How can we ensure that the benefits of genetic research are equitably distributed, rather than solely profiting corporations?
• What safeguards are necessary to prevent discrimination based on genetic information in areas like insurance or employment?